Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — Q1 FY2016 Earnings Presentation

30 slides from Daiichi Sankyo's earnings presentation, Jul 29, 2016

  1. Slide 1: Top Management Presentation: Financial Results of FY2016 Q1

    Top Management Presentation Financial Results of FY2016 Q1 DAIICHI SANKYO CO., LTD Joji Nakayama President and CEO July 29, 2016

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements  Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi

  3. Slide 3: Agenda

    Agenda  FY2016 Q1 Financial Results  Major Management Topics Edoxaban Update Expansion of Product Portfolio in Japan Enrichment of Shareholder Returns Securing Stable, Low Cost Funding R&D Topics 2

  4. Slide 4: FY2016 Q1 Financial Results

    FY2016 Q1 Financial Results 3

  5. Slide 5: Overview of FY2016 Q1 Results

    Overview of FY2016 Q1 Results (JPY Bn) FY2015 Q1 Results FY2016 Q1 Results YoY +1.1% Revenue 238.4 241.0 +2.6 Cost of Sales 74.0 77.6 +3.7 SG&A Expenses 71.6 69.5 -2.1 R&D Expenses 43.7 46.6 +2.9 -3.8% Operating Profit 49.1 47.3 -1.9 Profit before Tax 45.2 45.2 0.0 -12.4% Profit attributable to owne

  6. Slide 6: Revenue

    Revenue Increased by 2.6 Bn JPY despite negative effects of NHI price revision, growing numbers of generic drug prescriptions, and yen appreciation, revenue increased due to growth in sales of mainstay products in Japan, US, Europe and Asia (JPY Bn) FY2015 Results 238.4 Japan Japan Positive : Teneli

  7. Slide 7: Operating Profit

    Operating Profit Slightly decreased by 1.9 Bn JPY as special items (Gain on sale of fixed assets etc.) were included in FY2015, despite of US sales operation’s cost reduction and positive forex impact (JPY Bn) FY2015 Results 49.1 Revenue +2.6 incl. forex impact -12.6 Revenue 49.1 2.6 Cost of Sales i

  8. Slide 8: Profit Attributable to Owners of the Company

    Profit Attributable to Owners of the Company Decreased by 4.3 Bn JPY due to increase of income taxes caused by decrease in R&D tax credit (JPY Bn) FY2015 Results 34.9 Financial Income / Expenses -1.9 Operating Profit 1.9 FY2015: Expenses relating to the sales of Sun Pharma shares etc. FY2016: Increa

  9. Slide 9: Major Business Units

    Major Business Units (JPY Bn) FY2015 FY2016 vs. Forecast YoY Q1 Results Q1 Results (%) Japan 114.2 123.4 +9.2 24.9% Daiichi Sankyo Healthcare 10.8 14.8 +4.0 24.7% Daiichi Sankyo Inc. 48.0 40.7 -7.3 33.1% Olmesartan 28.8 23.2 -5.6 40.0% Welchol 13.5 10.0 -3.6 27.0% Effient 5.2 6.0 +0.8 - Savaysa -0.3

  10. Slide 10: Major Products in Japan

    Major Products in Japan (JPY Bn) FY2015 FY2016 vs. Forecast YoY Q1 Results Q1 Results (%) Nexium ulcer treatment 19.1 21.0 +1.9 26.3% Olmetec antihypertensive agent 18.5 18.3 -0.2 26.8% Alzheimer’s disease Memary treatment 10.2 12.1 +1.9 23.8% Loxonin anti-inflammatory analgesic 12.6 10.3 -2.3 27.8%

  11. Slide 11: Major Management Topics

    Dalichi-Sankyo Major Management Topics 10

  12. Slide 12: Edoxaban: Japan

    Edoxaban: Japan Latest market share reached: 13.5% (Apr. 2016 ~ Jun. 2016) (%) 50 40 30 Lixiana Product A Product B 20 Product C Market Share: 13.5% 10 0 FY2014Q2 FY2014Q3 FY2014Q4 FY2015Q1 FY2015Q2 FY2015Q3 FY2015Q4 FY2016Q1 ©2016 IMS Health Calculated based on JPM 2014. Oct.-2016. Jun. Reprinted w

  13. Slide 13: Edoxaban: Status in Other Regions

    Edoxaban: Status in Other Regions  Launched countries Japan, U.S., Switzerland, the U.K, Germany, Ireland, the Netherlands, South Korea  Approved countries (currently preparing for launch) Taiwan, Hong Kong  Countries where applications for approval are underway Brazil, Thailand, Australia, China

  14. Slide 14: Expansion of Product Portfolio in Japan

    Expansion of Product Portfolio in Japan Approval for anti epilepsy VIMPAT (lacosamide) Indications  As an adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adult patients with epilepsy who have not obtained sufficient response to other antiep

  15. Slide 15: Enrichment of Shareholder Returns

    Enrichment of Shareholder Returns Shareholder Returns Policy during 5YBP*  Total return ratio: 100% or more  Annual ordinary dividend: more than 70 JPY  Flexible acquisition of own shares * 5YBP: 5-year Business Plan (FY2016 - FY2020) Based on the policy, acquisition of own shares is ongoing  Ac

  16. Slide 16: Securing Stable, Low Cost Funding

    Securing Stable, Low Cost Funding Under the environment of continuous low interest rates, became the first Japanese healthcare sector’s company to secure stable, low cost funds by issuing super-long-term bonds Issuance of unsecured straight bonds  Total amount of issue: 100.0 billion JPY (75.0 bill

  17. Slide 17: R&D Topics

    R&D Topics 16

  18. Slide 18: Steady progress of pipeline in late development phase: CL-108

    Steady progress of pipeline in late development phase: CL-108 CL-108  Novel, bi-layered tablet containing hydrocodone, acetaminophen and promethazine to treat moderate to severe pain and prevent or reduce opioid-induced nausea and vomiting (OINV)  NDA was submitted to FDA in March 2016 and current

  19. Slide 19: CL-108: Phase 3 study results

    CL-108: Phase 3 study results The study confirmed that CL-108 is a safe and effective analgesic while reducing or preventing OINV in patients with moderate to severe pain following bunionectomy Patients taking CL-108 experienced Patients taking CL-108 experienced significant pain relief compared wit

  20. Slide 20: U.S. Pain Market Holds Great Opportunity

    U.S. Pain Market Holds Great Opportunity Large, Growing Market with Diverse Segments U.S. Pain Market Gross Sales (US$ Billion) Mirogabalin SNRIs† TCAs† 1% Anesthetics 2015: $28 Billion Anti-migraine 1% CL-108 ‘07-’15 CAGR 6.6% 28 Pregabalin 5% 2% 26 40% experienced Others 3% Acute OINV 23 Anti-epil

  21. Slide 21: Steady progress of pipeline in late development phase: CHS-0214

    Steady progress of pipeline in late development phase: CHS-0214 CHS-0214  CHS-0214 is a proposed biosimilar of etanercept (Embrel)  CHS-0214 is fusion protein comprising the soluble human TNF receptor and the Fc region of human IgG1  Competitive binder of tumor necrosis factor  Phase 1 studies h

  22. Slide 22: CHS-0214: Results of the phase 3 study

    CHS-0214: Results of the phase 3 study Confirmed bioequivalence btw CHS-0214 and etanercept  Efficacy: CHS-0214 met the predefined criteria of equivalency in terms of ACR20* and DAS28-CRP** *ACR20 and **DAS28-CPR are the measures to evaluate disease activity for RA  Safety and Immunogenicity: CHS-

  23. Slide 23: Steady progress of pipeline in late development phase: DS-8500

    Steady progress of pipeline in late development phase: DS-8500 DS-8500 GPR119 activator  Anti-diabetic agent (DS-8500)  GPR119 agonist Small Pancreas intestine  Amplify glucose-stimulated bcell insulin secretion Lcell cAMP  Improve β-cell function PYY, GLP-1 - degradation  Stimulate GLP-1 secre

  24. Slide 24: DS-8500: Results of the Japan phase 2a study

    DS-8500: Results of the Japan phase 2a study No tachyphylaxis was observed during the treatment for 28 days Change of twenty-four-hour weighted mean glucose Time point 10 Day -1 Day 14 Day 28 Change in 24hr-WMG from Day -1 (mg/dL) 5 0 -5 P=0.0439 P=0.0093 -10 -15 P=0.0003 P=0.0002 -20 Placebo (n = 3

  25. Slide 25: DS-8500: Ongoing Phase 2b study design

    DS-8500: Ongoing Phase 2b study design Japan monotherapy TLR: FY2016 Q4 12wks Enroll Enroll Placebo treated T2DM naïve T2DM patients patients DS-8500 25 mg Placebo R DS-8500 50 mg - 8wks - 2wks Washout period Run-in period DS-8500 75 mg NCT02628392 R; randomization Sitagliptin 50 mg Visit at 2,4,8,

  26. Slide 26: Application of advanced technologies: G47Δ (DS-1647)

    Application of advanced technologies to create innovative medicine: G47Δ (DS-1647) Initiate in earnest the development of treatment by oncolytic virus, G47Δ (DS-1647)  In collaboration with Professor Todo of Institute of Medical Science, the University of Tokyo, DS has initiated the development of

  27. Slide 27: Application of G47Δ virus for cancer treatment

    Application of G47Δ virus for cancer treatment  History  CY2009 - 14 Phase 1/2 study to treat progressive glioblastoma* conducted by Prof. Todo. Confirmed safety of the treatment of G47Δ  CY2015 Initiated investigator-initiated phase 2 by Prof. Todo which could be a registration study to treat gl

  28. Slide 28: Major R&D milestone events

    Major R&D milestone events Project Indication/Study Event Target Pain/Opioid-induced nausea and vomiting PDUFA date CL-108 (US) Approval Jan. 31, 2017 CHS-0214 Rheumatoid arthritis (JP) NDA FY2016 (etanercept BS) Denosumab Rheumatoid arthritis (JP) NDA FY2016 Ischemic cerebrovascular disease Prasugr

  29. Slide 29: Major R&D Pipeline

    Major R&D Pipeline As of July 2016 Therapeutic area Phase 1 Phase 2 Phase 3 Application  DS-3032 (US/JP) DS-8895 (JP)  Patritumab (EU)  Tivantinib (US/EU) (MDM2 inhibitor) (Anti-EPHA2 antibody) (U3-1287 / Anti-HER3 antibody) (ARQ 197 / HCC / MET inhibitor)  PLX7486 (US)  DS-8273 (US)  Denosum

  30. Slide 30: Contact address regarding this material

    Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126

Daiichi Sankyo Company — Q1 FY2016 Earnings Presentation on 6ix